The Mayo Clinic Cancer Center (MCCC) considers the Developmental Funds to be one of the most critical components of Cancer Center Support Grant (CCSG) support. Together with institutionally derived MCCC discretionary funds end the annual grant support from the Fraternal Order of Eagles, these funds have supported recruitment of new research faculty, shared resource development, end the initiation of research projects or generation of pilot data for subsequent peer review grant applications.Given the smell size of the CCSG Developmental Fund pool relative to the substantial expansion realized over the lest funding period, institutionally-derived MCCC discretionary funds end philanthropic sources have contributed more than 90% of the funding needed for pilot projects, program or shared resource initiation, end ell funding for instrumentation end new laboratory set-up costs. Processes are firmly established in the MCCC to solicit end review proposals for CCSG Developmental Fund support. Funding is predicated on scientific merit, programmatic relevance, MCCC strategic priorities end, in the case of shared resource development, the unambiguous need of investigators with peer reviewed funding. The same level of funding is requested in the next project period to support initiatives in the following categories: ? Continued recruitment of outstanding new research faculty. ? Pilot projects - to eneble the MCCC to pursue outstanding science leading to peer review funding; including highly innovative but high-risk proposals that might otherwise not receive funding ? Development of shared resources - to ensure the scientific vitality of MCCC investigators end programs Support of Staff Investigators- MCCC is requesting partial salary support for three Staff Investigators. Neither of these three individuals have e leadership position within the Center, its programs, or its shared resources however, they are judged to be critical by the MCCC leadership to the operation of the Cancer Center for different reasons. The MCCC's Developmental Fund request represents approximately 5.8% of the direct costs requested.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682953
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$299,918
Indirect Cost
$111,446
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Basch, Ethan; Rogak, Lauren J; Dueck, Amylou C (2016) Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 38:821-30
Renner, Danielle N; Malo, Courtney S; Jin, Fang et al. (2016) Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model. Neurotherapeutics 13:226-36
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Amirian, E Susan; Zhou, Renke; Wrensch, Margaret R et al. (2016) Approaching a Scientific Consensus on the Association between Allergies and Glioma Risk: A Report from the Glioma International Case-Control Study. Cancer Epidemiol Biomarkers Prev 25:282-90
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Ye, Zi; Austin, Erin; Schaid, Daniel J et al. (2016) A multi-locus genetic risk score for abdominal aortic aneurysm. Atherosclerosis 246:274-9
McCormack, Valerie A; Burton, Anya; dos-Santos-Silva, Isabel et al. (2016) International Consortium on Mammographic Density: Methodology and population diversity captured across 22 countries. Cancer Epidemiol 40:141-51
Basal, E; Ayeni, T; Zhang, Q et al. (2016) Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Curr Mol Med 16:222-31
Vaidhyanathan, Shruthi; Wilken-Resman, Brynna; Ma, Daniel J et al. (2016) Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases. J Pharmacol Exp Ther 356:251-9
Yoon, H H; Foster, N R; Meyers, J P et al. (2016) Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 27:339-44

Showing the most recent 10 out of 948 publications